When and how to treat acute hepatitis C? (Articolo in rivista)

Type

• Prodotto della ricerca (Classe)
• Articolo in rivista (Classe)

Label

• When and how to treat acute hepatitis C? (Articolo in rivista) (literal)

Anno

• 2003-01-01T00:00:00+01:00 (literal)

Alternative label

• Licata A, Di Bona D, Schepis F, Shahied L, Craxi A, Camma C. (2003)
  When and how to treat acute hepatitis C?
  in Journal of hepatology (Print)
  (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori

• Licata A, Di Bona D, Schepis F, Shahied L, Craxi A, Camma C. (literal)

Pagina inizio

• 1056 (literal)

Pagina fine

• 1062 (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroVolume

• 39 (literal)

Rivista

• Journal of hepatology (Rivista)

Note

• ISI Web of Science (WOS) (literal)

Titolo

• When and how to treat acute hepatitis C? (literal)

Abstract

• BACKGROUND: Appropriate treatment of acute hepatitis C is still a matter of controversy due to the lack of large controlled trials. AIM: To assess the effectiveness of interferon as treatment for acute hepatitis C by meta-analysis. METHODS: MEDLINE search (1985-2002) was supplemented with manual searches of reference lists. Studies were included if they were controlled trials comparing interferon to no treatment and if they included patients with either post-transfusion or sporadic acute hepatitis C. Twelve trials were analyzed (414 patients). The outcome assessed was the sustained virological response (SVR) rate (undetectable hepatitis C virus RNA in serum at least 6 months after cessation of therapy). RESULTS: Interferon significantly increased the SVR (risk difference 49%; 95% confidence interval 32.9-65%) in comparison to no treatment. The risk difference of SVR increased from 5 to 90% when trials were ordered by increasing interferon weekly dose. Delaying therapy by 8-12 weeks after the onset of disease does not compromise the SVR rate. CONCLUSIONS: Current evidence is sufficient to recommend interferon treatment of patients with acute hepatitis C. A later initiation of therapy yields the same likelihood of response as early treatment. A daily induction dose during the 1st month is the best option of treatment. (literal)

Prodotto di

• Istituto di biomedicina e di immunologia molecolare \"Alberto Monroy\" (IBIM) (Istituto)

Autore CNR

• CALOGERO CAMMA' (Unità di personale interno)

Incoming links:

Prodotto

• Istituto di biomedicina e di immunologia molecolare \"Alberto Monroy\" (IBIM) (Istituto)

Autore CNR di

• CALOGERO CAMMA' (Unità di personale interno)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#rivistaDi

• Journal of hepatology (Rivista)